Thema: US45256X1037
IBRX, US45256X1037
chart-840333_1920.jpg - Foto: THN
ImmunityBio stock slips 7% in October despite trial progress
ImmunityBio stock faces a November trial readout after database lock in a 366-patient study. The FDA recently broadened ANKTIVA's bladder-cancer indication.
ad-hoc-news.de, heute 18:44 Uhr
IBRX, US45256X1037
H.C. Wainwright keeps USD 15.00 target for ImmunityBio stock ...
Results are set for November 3, 2026, with USD 51.24 million in second-quarter revenue. ImmunityBio stock costs EUR 7.36 on October 24, 2026.
ad-hoc-news.de, 24.10.26 21:05 Uhr
IBRX, US45256X1037
ImmunityBio reports 84 percent cystectomy avoidance. Six ...
Results are scheduled for November 3, 2026. ImmunityBio stock costs EUR 7.87 on October 20, 2026, 18.87 percent below its 52-week high.
ad-hoc-news.de, 20.10.26 20:08 Uhr
IBRX, US45256X1037
Jefferies lifts target for ImmunityBio stock to USD 14.00 ...
In the second quarter of 2026, revenue reached USD 50.70 million, up 92.00 percent. ImmunityBio stock costs EUR 8.89 on October 15, 2026 at 9:21 p.m. CEST.
ad-hoc-news.de, 15.10.26 21:33 Uhr
IBRX, US45256X1037
ImmunityBio proposes 560,000-share sale: what it means for ...
A 560,000-share sale was proposed on October 5, 2026. For ImmunityBio stock this means USD 50.7 million in second-quarter revenue, up 92 percent.
ad-hoc-news.de, 06.10.26 06:41 Uhr
IBRX, US45256X1037
Jefferies upgrades ImmunityBio stock to Strong Buy
Seven analysts set a USD 14.20 average target. ImmunityBio stock cost EUR 9.21 on October 2, 2026, plus 11.77 percent versus EUR 8.24.
ad-hoc-news.de, 02.10.26 18:08 Uhr
ImmunityBio, Gains
ImmunityBio Gains Strategic Foothold in Saudi Pharmaceutical ...
ImmunityBio US45256X1037
boerse-global.de, 17.02.26 22:54 Uhr
ImmunityBio’s, Brain
ImmunityBio’s Brain Cancer Therapy Shows Promising Early ...
